Archive · 1 Oct 2026
Aurobindo Arm Launches Adquey, Enters U.S. Dermatology Market
Acrotech Biopharma has introduced a medicine called Adquey in the United States.
Adquey is for people with mild-to-moderate atopic dermatitis, a skin condition.
The launch is Acrotech’s first move into the U.S. dermatology market.
The company is also creating a new team focused only on skin-care medicines.
This team will handle marketing, sales and work with health professionals.
Acrotech says it wants to build a dermatology business beyond just one product.
Adquey will compete in a market estimated at about $1.3 billion.
The company described the launch as an important milestone.
Acrotech Biopharma, a subsidiary of Aurobindo Pharma, launched Adquey in the United States.
Adquey is intended to treat mild-to-moderate atopic dermatitis.
The launch marks Acrotech’s entry into the U.S. dermatology market.
Acrotech established a dedicated dermatology business unit covering marketing, sales and field engagement.
The U.S. market for the treatment area is estimated at about $1.3 billion for the 12 months ending July 2026, according to IQVIA MAT.
- Who
- Acrotech Biopharma, a subsidiary of Aurobindo Pharma, launched Adquey.
- What
- Adquey was launched to treat mild-to-moderate atopic dermatitis, alongside the creation of a dedicated dermatology business unit.
- When
- The launch was reported on October 1, 2026.
- Where
- The United States.
- Why
- Acrotech aims to enter the U.S. dermatology market and build capabilities for additional dermatology opportunities.
- Company
- Acrotech Biopharma, a subsidiary of Aurobindo Pharma
- Product
- Adquey
- Indication
- Mild-to-moderate atopic dermatitis
- Market
- U.S. dermatology market
- Market estimate
- About $1.3 billion for the 12 months ending July 2026
- Market data source
- IQVIA MAT
- New business unit
- Dedicated dermatology unit with marketing, sales and field-based capabilities